Inventisbio Co., Ltd. (688382)

Overview

InventisBio Co., Limited is a dynamic biotechnology entity operating at the forefront of the pharmaceutical industry, with a focus on pioneering the discovery and development of innovative therapeutics aimed at combating cancer and metabolic diseases. Founded in 2013 and with its headquarters nestled in Pudong, China, InventisBio has expanded its reach to have a significant presence in both the Chinese and United States markets. The company’s drive for innovation is further cemented by its strategic collaboration with Betta Pharmaceuticals, aimed at enhancing its research and development capabilities to meet the urgent needs of patients afflicted with these life-altering diseases.

Products and Services

InventisBio has curated a robust portfolio of drug candidates targeting various cancer types and metabolic diseases, showcasing the company’s commitment to addressing unmet medical needs through rigorous research and clinical trials.

• BPI-D0316: Currently in Phase III clinical trials, BPI-D0316 represents InventisBio’s forefront oncology candidate aimed at treating non-small cell lung cancer (NSCLC). The progression to Phase III trials underscores the potential efficacy and safety profile BPI-D0316 could offer to NSCLC patients, reflecting a significant stride towards improving survival and quality of life.
• D-0502: This candidate is undergoing Phase I clinical trials targeting the treatment of breast cancer, indicating the early stages of development and evaluation for safety and preliminary efficacy. D-0502 exemplifies InventisBio’s dedication to expanding its cancer treatment portfolio, with a specific emphasis on addressing breast cancer, a leading cause of cancer-related deaths among women worldwide.
• D-1553: Also in Phase I clinical trials, D-1553 is being developed for a range of cancer indications, including NSCLC and colorectal cancer. The initiation of these trials signifies InventisBio's commitment to leveraging scientific advancements to tackle cancers with high unmet need, potentially offering new hopes for patients with limited treatment options.
• D-0120: Representing InventisBio’s ventures into metabolic diseases, D-0120 is a drug candidate in Phase I and II clinical trials for the treatment of hyperuricemia and gout. The dual-phase trials highlight the company's approach to addressing chronic conditions like gout, which significantly impacts patients' quality of life, through innovative therapeutic solutions.